|
Blood pressure lowering medication at baseline and end of follow-up |
||||
| Background metformin |
Background sulfonylurea |
|||
|
|
|
|||
| + rosiglitazone |
+ sulfonylurea |
+ rosiglitazone |
+ metformin |
|
|
|
||||
| Modified ITT population (n) |
176 |
165 |
160 |
167 |
| Type of medication (n (%)) |
||||
| Baseline |
||||
| Any BP medication |
119 (68) |
112 (68) |
104 (65) |
114 (68) |
| ACEi/ARB |
91 (52) |
83 (50) |
80 (50) |
88 (53) |
| β-blocker |
44 (25) |
42 (25) |
34 (21) |
43 (26) |
| CCB |
37 (21) |
33 (20) |
28 (17) |
36 (22) |
| Diuretics |
28 (16) |
34 (21) |
26 (16) |
38 (23) |
| End of follow-up* |
||||
| Any BP medication |
131 (74) |
124 (75) |
119 (74) |
121 (72) |
| ACEi/ARB |
99 (56) |
93 (56) |
89 (56) |
92 (55) |
| β-blocker |
51 (29) |
53 (32) |
40 (25) |
46 (27) |
| CCB |
47 (27) |
39 (24) |
32 (20) |
40 (24) |
| Diuretics |
48 (27) |
39 (24) |
34 (21) |
41 (25) |
| Number of drug classes (n (%)) |
||||
| Baseline |
||||
| 0 |
57 (32) |
53 (32) |
56 (35) |
53 (32) |
| 1 |
62 (35) |
47 (28) |
51 (32) |
47 (28) |
| 2 |
34 (19) |
45 (27) |
37 (23) |
43 (26) |
| 3 |
17 (10) |
15 (9) |
14 (9) |
20 (12) |
| > 3 |
6 (3) |
5 (3) |
2 (1) |
4 (2) |
| End of follow-up |
||||
| 0 |
45 (25) |
41 (25) |
41 (26) |
46 (27) |
| 1 |
57 (32) |
47 (28) |
58 (36) |
45 (27) |
| 2 |
34 (19) |
47 (28) |
41 (26) |
50 (30) |
| 3 |
27 (15) |
22 (13) |
15 (9) |
19 (11) |
| > 3 |
13 (7) |
8 (5) |
5 (3) |
7 (4) |
|
Data are n or n (%). ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker. *End of follow-up refers to time of stopping dual combination therapy or 12 months, whichever is sooner | ||||
Komajda et al. Cardiovascular Diabetology 2008 7:10 doi:10.1186/1475-2840-7-10 |
||||